Protective effects of zonisamide against rotenone-induced neurotoxicity

Neurochemical Research

Volumn 38, Issue 12, 2013, Pages 2631-2639

  Condello, Salvatore ^a   Currò, Monica ^a   Ferlazzo, Nadia ^a   Costa, Gregorio ^b   Visalli, Giuseppa ^a   Caccamo, Daniela ^a   Pisani, Laura Rosa ^b   Costa, Cinzia ^c,d   Calabresi, Paolo ^c,d   Ientile, Riccardo ^a   Pisani, Francesco ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Apoptosis; Mitochondrial impairment; Neuroprotection; Oxidative stress; Zonisamide

Indexed keywords

ACETYLCYSTEINE; CASPASE 3; REACTIVE OXYGEN METABOLITE; ROTENONE; ZONISAMIDE;

ANTIAPOPTOTIC EFFECT; APOPTOSIS; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; NERVE CELL; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY; PRIORITY JOURNAL;

APOPTOSIS; CELL LINE, TUMOR; HUMANS; ISOXAZOLES; MEMBRANE POTENTIAL, MITOCHONDRIAL; NERVOUS SYSTEM; REACTIVE OXYGEN SPECIES; ROTENONE;

EID: 84890314261     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-013-1181-2     Document Type: Article

References (53)

1. Mattson MP (2008) Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N Y Acad Sci 1144:97-112. doi: 10.1196/annals.1418. 005
2. Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C et al (2004) Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279:18614-18622. doi: 10.1074/jbc.M401135200
3. Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E et al (2005) Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain 128:2654-2664. doi: 10.1093/brain/awh584
4. Chinta SJ, Kumar JM, Zhang H, Forman HJ, Andersen JK (2006) Up-regulation of gamma-glutamyl transpeptidase activity following glutathione depletion has a compensatory rather than an inhibitory effect on mitochondrial complex I activity: implications for Parkinson's disease. Free Radic Biol Med 40:1557-1563. doi: 10.1016/j.freeradbiomed.2005.12.023
5. Jellinger KA (2000) Cell death mechanisms in Parkinson's disease. J Neural Transm 107:1-29
6. Schapira AHV (2010) Complex I: inhibitors, inhibition and neurodegeneration. Exp Neurol 224:331-335. doi: 10.1016/j.expneurol.2010.03.028
7. Greenamyre JT, Betarbet R, Sherer TB (2003) The rotenone model of Parkinson's disease: genes, environment and mitochondria. Parkinsonism Relat Disord 9(Suppl 2):S59-S64
8. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV et al (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3:1301-1306. doi: 10.1038/81834
9. Martins JB, de Bastos ML, Carvalho F, Capela JP (2013) Differential effects of methyl-4-phenylpyridinium ion, rotenone, and paraquat on differentiated SH-SY5Y cells. J Toxicol 2013:347312. doi: 10.1155/2013/347312
10. Costa C, Belcastro V, Tozzi A, Di Filippo M, Tantucci M et al (2008) Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition. J Neurosci 28:8040-8052. doi: 10.1523/JNEUROSCI.1947-08.2008
11. Biton V (2007) Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 30:230-240. doi: 10.1097/wnf.0b013e3180413d7d
12. Johannessen Landmark C (2008) Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 22:27-47
13. Kothare SV, Kaleyias J (2008) Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol 4:493-506. doi: 10.1517/17425255.4.4.493
14. Costa C, Tozzi A, Luchetti E, Siliquini S, Belcastro V et al (2010) Electrophysiological actions of zonisamide on striatal neurons: selective neuroprotection against complex I mitochondrial dysfunction. Exp Neurol 221:217-224. doi: 10.1016/j.expneurol.2009.11.002
15. Sonsalla PK, Wong L-Y, Winnik B, Buckley B (2010) The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol 221:329-334. doi: 10.1016/j.expneurol.2009.11.018
16. Condello S, Currò M, Ferlazzo N, Caccamo D, Satriano J et al (2011) Agmatine effects on mitochondrial membrane potential andNF-κB activation protect against rotenone-induced cell damage in human neuronal-like SH-SY5Y cells. J Neurochem 116:67-75. doi: 10.1111/j.1471-4159.2010.07085.x
17. Shimizu S, Narita M, Tsujimoto Y (1999) Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399:483-487. doi: 10.1038/20959
18. Yu Z, Li W, Hillman J, Brunk UT (2004) Human neuroblastoma (SH-SY5Y) cells are highly sensitive to the lysosomotropic aldehyde 3-aminopropanal. Brain Res 1016:163-169. doi: 10.1016/j.brainres.2004.04.075
19. Galluzzi L, Morselli E, Kepp O, Kroemer G (2009) Targeting post-mitochondrial effectors of apoptosis for neuroprotection. Biochim Biophys Acta 1787:402-413. doi: 10.1016/j.bbabio.2008.09.006
20. Büeler H (2009) Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Exp Neurol 218:235-246. doi: 10.1016/j.expneurol.2009.03.006
21. Nisticò R, Mehdawy B, Piccirilli S, Mercuri N (2011) Paraquat- and rotenone-induced models of Parkinson's disease. Int J Immunopathol Pharmacol 24:313-322
22. Blesa J, Phani S, Jackson-Lewis V, Przedborski S (2012) Classic and new animal models of Parkinson's disease. J Biomed Biotechnol 2012:845618. doi: 10.1155/2012/845618
23. Imamura K, Takeshima T, Kashiwaya Y, Nakaso K, Nakashima K (2006) D-beta-hydroxybutyrate protects dopaminergic SH-SY5Y cells in a rotenone model of Parkinson's disease. J Neurosci Res 84:1376-1384. doi: 10.1002/jnr.21021
24. Borland MK, Trimmer PA, Rubinstein JD, Keeney PM, Mohanakumar K et al (2008) Chronic, low-dose rotenone reproduces Lewy neurites found in early stages of Parkinson's disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells. Mol Neurodegener 3:21. doi: 10.1186/1750-1326-3-21
25. Giordano S, Lee J, Darley-Usmar VM, Zhang J (2012) Distinct effects of rotenone, 1-methyl-4-phenylpyridinium and 6-hydroxydopamine on cellular bioenergetics and cell death. PLoS ONE 7:e44610. doi: 10.1371/journal.pone. 0044610
26. Kitao Y, Matsuyama T, Takano K, Tabata Y, Yoshimoto T et al (2007) Does ORP150/HSP12A protect dopaminergic neurons against MPTP/MPP(+)-induced neurotoxicity? Antioxid Redox Signal 9:589-595. doi: 10.1089/ars 2006.1518
27. Kyratzi E, Pavlaki M, Kontostavlaki D, Rideout HJ, Stefanis L (2007) Differential effects of Parkin and its mutants on protein aggregation, the ubiquitin-proteasome system, and neuronal cell death in human neuroblastoma cells. J Neurochem 102:1292-1303. doi: 10.1111/j.1471-4159.2007.04620.x
28. Sung JY, Lee HJ, Jeong EI, Oh Y, Park J et al (2007) Alpha-synuclein overexpression reduces gap junctional intercellular communication in dopaminergic neuroblastoma cells. Neurosci Lett 416:289-293. doi: 10.1016/j.neulet.2007.02.025
29. Fall CP, Bennett JP Jr (1999) Characterization and time course of MPP+ -induced apoptosis in human SH-SY5Y neuroblastoma cells. J Neurosci Res 55:620-628
30. Li WG, Miller FJ Jr, Zhang HJ, Spitz DR, Oberley LW et al (2001) H(2)O(2)-induced O(2) production by a non-phagocytic NAD(P)H oxidase causes oxidant injury. J Biol Chem 276:29251-29256. doi: 10.1074/jbc.M102124200
31. Mizutani H, Tada-Oikawa S, Hiraku Y, Oikawa S, Kojima M et al (2002) Mechanism of apoptosis induced by a new topoisomerase inhibitor through the generation of hydrogen peroxide. J Biol Chem 277:30684-30689. doi: 10.1074/jbc.M204353200
32. Boveris A (1977) Mitochondrial production of superoxide radical and hydrogen peroxide. Adv Exp Med Biol 78:67-82
33. Turrens JF, Boveris A (1980) Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem J 191:421-427
34. Tada-Oikawa S, Hiraku Y, Kawanishi M, Kawanishi S (2003) Mechanism for generation of hydrogen peroxide and change of mitochondrial membrane potential during rotenone-induced apoptosis. Life Sci 73:3277-3288
35. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR et al (2003) Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 23:10756-10764
36. Asanuma M, Miyazaki I, Diaz-Corrales FJ, Miyoshi K, Ogawa N et al (2008) Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation. Neurosci Res 60:106-113. doi: 10.1016/j.neures.2007.10.002
37. Kawajiri S, Machida Y, Saiki S, Sato S, Hattori N (2010) Zonisamide reduces cell death in SH-SY5Y cells via an anti-apoptotic effect and by upregulating MnSOD. Neurosci Lett 481:88-91. doi: 10.1016/j.neulet.2010.06.058
38. Yürekli VA, Gürler S, NazIroǧlu M, Uǧuz AC, Koyuncuoǧlu HR (2013) Zonisamide attenuates MPP+ -induced oxidative toxicity through modulation of Ca2+ signaling and caspase-3 activity in neuronal PC12 cells. Cell Mol Neurobiol 33:205-212. doi: 10.1007/s10571-012-9886-3
39. Pena C, Zhou Y, Lust D, Pilar G (2001) Restoration of mitochondrial function reverses developmental neuronal death in vitro. J Comp Neurol 440:156-176
40. Orth M, Schapira AHV (2002) Mitochondrial involvement in Parkinson's disease. Neurochem Int 40:533-541
41. Hu J-H, Zhu X-Z (2007) Rotenone-induced neurotoxicity of THP-1 cells requires production of reactive oxygen species and activation of phosphatidylinositol 3-kinase. Brain Res 1153:12-19. doi: 10.1016/j.brainres. 2007.03.006
42. Watabe M, Nakaki T (2007) Mitochondrial complex I inhibitor rotenone-elicited dopamine redistribution from vesicles to cytosol in human dopaminergic SH-SY5Y cells. J Pharmacol Exp Ther 323:499-507. doi: 10.1124/jpet.107.127597
43. Das A, McDowell M, O'Dell CM, Busch ME, Smith JA et al (2010) Post-treatment with voltage-gated Na(+) channel blocker attenuates kainic acid-induced apoptosis in rat primary hippocampal neurons. Neurochem Res 35:2175-2183. doi: 10.1007/s11064-010-0321-1
44. Miwa H, Kondo T (2011) T-type calcium channel as a new therapeutic target for tremor. Cerebellum 10:563-569. doi: 10.1007/s12311-011-0277-y
45. Willmore LJ (2005) Antiepileptic drugs and neuroprotection: current status and future roles. Epilepsy Behav 7(Suppl 3):S25-S28. doi: 10.1016/j.yebeh.2005.08.006
46. Murata M (2010) Zonisamide: a new drug for Parkinson's disease. Drugs Today 46:251-258. doi: 10.1358/dot.2010.46.4.1490077
47. Rösler TW, Arias-Carrión O, Höglinger GU (2010) Zonisamide: aspects in neuroprotection. Exp Neurol 224:336-339. doi: 10.1016/j.expneurol.2010.04.017
48. Calabresi P, Picconi B, Tozzi A, Di Filippo M (2007) Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 30:211-219. doi: 10.1016/j.tins.2007.03.001
49. Di Filippo M, Picconi B, Costa C, Bagetta V, Tantucci M et al (2006) Pathways of neurodegeneration and experimental models of basal ganglia disorders: downstream effects of mitochondrial inhibition. Eur J Pharmacol 545:65-72. doi: 10.1016/j.ejphar.2006.06.024
50. Yokoyama H, Yano R, Kuroiwa H, Tsukada T, Uchida H et al (2010) Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice. Metab Brain Dis 25:305-313. doi: 10.1007/s11011-010-9212-z
51. Murata M, Horiuchi E, Kanazawa I (2001) Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci Res 41:397-399
52. Murata M, Hasegawa K, Kanazawa I, Japan Zonisamide on PD Study Group (2007) Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 68:45-50. doi: 10.1212/01.wnl.0000250236.75053.16
53. Bermejo PE, Ruiz-Huete C, Anciones B (2010) Zonisamide in managing impulse control disorders in Parkinson's disease. J Neurol 257:1682-1685. doi: 10.1007/s00415-010-5603-7